Clinical pharmacokinetics on canagliflozin: a systematic review of in-vitro and in-vivo studies
Expert Review of Clinical Pharmacology · 02.12.2025 · 18 (12) · 1079-1094
DOI: 10.1080/17512433.2025.2597512 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 04.12.2025. Verfasst von Noor E Eden und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Hauptthemen laut MEDLINE: Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Canagliflozin (CFZ), is a commonly used sodium-glucose cotransporter-2 inhibitor drug for the management of type 2 diabetes mellitus (T2DM). This review comprehensively compiles existing research studies regarding the clinical pharmacokinetic (PK) behavior of canagliflozin, primarily focusing on exploring effects of different disease conditions, potential drug interactions, and genetic polymorphism. AREAS COVERED: A comprehensive review of scholarly literature was conducted by using leading databases, i.e. Google Scholar, Science Direct, PubMed, and Cochrane, to identify clinical PK studies of CFZ. The comprehensive literature search identified 25 articles that met the inclusion standards. A linear relationship was observed between the administered doses and PK parameters such as area under the curve from time 0 to infinity (AUC0-∞) and maximum plasma concentration (Cmax). The findings from T2DM patients with moderate renal impairment displayed a 27% increase in AUC0-∞ of canagliflozin. Furthermore, co-administration of CFZ with rifampin in humans reduced Cmax by 28%, while with telmisartan in rats, CL/F decreased 31.1% initially, but increased 62.9% after 7 days. EXPERT OPINION: This review integrates all significant human PK parameters of CFZ by combining findings from existing studies, allowing researchers to develop and evaluate PK models for recommending model-based dose optimization. PROTOCOL REGISTRATION: CRD420251054714.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
- Allama Iqbal Campus, University College of Pharmacy, University of the Punjab, Lahore, Pakistan.
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Zitieren
APA
Eden, N. E., Zamir, A., Saeed, H., Alqahtani, F., & Rasool, M. F. (2025). Clinical pharmacokinetics on canagliflozin: a systematic review of in-vitro and in-vivo studies. Expert Review of Clinical Pharmacology, 18(12), 1079-1094. https://doi.org/10.1080/17512433.2025.2597512
Vancouver
Eden NE, Zamir A, Saeed H, Alqahtani F, Rasool MF. Clinical pharmacokinetics on canagliflozin: a systematic review of in-vitro and in-vivo studies. Expert Review of Clinical Pharmacology. 2025;18(12):1079-1094. doi:10.1080/17512433.2025.2597512
BibTeX
@article{Eden2025,
author = {Eden, Noor E and Zamir, Ammara and Saeed, Hamid and Alqahtani, Faleh and Rasool, Muhammad Fawad},
title = {Clinical pharmacokinetics on canagliflozin: a systematic review of in-vitro and in-vivo studies},
journal = {Expert Review of Clinical Pharmacology},
year = {2025},
volume = {18},
number = {12},
pages = {1079--1094},
doi = {10.1080/17512433.2025.2597512}
}
EUVIMED